Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | The definitive guide to multiple myeloma at ASH 2018: part III

Setting the threshold for MRD in MM and more consideration from ASH 2018
Interest continues to grow around to the role of measurable residual disease (MRD) in multiple myeloma (MM) and this has been made clear at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Mohamad Mohty, MD, PhD, from the University Pierre & Marie Curie, Paris, France, and Saad Usmani, MD, FACP, of the University of North Carolina School of Medicine, Chapel Hill, NC, share their views on MRD assessment, discussing the need for thresholds in its evaluation within a clinical setting. Together they review the practical implications of the various methods of MRD measurement including flow cytometry and next-generation sequencing. In addition, they consider the need for imaging, PET-CT, in disease assessment.